专利诉讼和解中反向支付的反垄断分析——兼评Schering-Plough及Tamoxifen反向支付案

Anti-Monopoly Analysis of Reverse Payment in Patent Litigation Settlement: Comments on Schering-Plough and Tamoxifen Cases

笔者认为,反向支付和解协议本质上是专利药公司与仿制药公司签订的横向限制竞争协议,是一种典型的本身违法行为,应当受到反垄断法的规制。

The authors hold that the reverse payment agreement is, in essence, an agreement contracted by both the brand drug company and the generic drug company to restrict horizontal competition. It is typically per se illegal, and shall be regulated by the anti-monopoly law.